Serial measurement of type-specific human papillomavirus load enables classification of cervical intraepithelial neoplasia lesions according to occurring human papillomavirus-induced pathway

European Journal of Cancer Prevention

Volumn 26, Issue 2, 2017, Pages 156-164

  Verhelst, Stefanie ^a   Poppe, Willy A J ^a   Bogers, Johannes J ^b   Depuydt, Christophe E ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b AML Laboratory   (Belgium)

Author keywords

cervical intraepithelial neoplasia; liquid based cytology; primary cervical cancer screening; real time quantitative PCR; viral load

Indexed keywords

ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LATENT PERIOD; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; MOLECULAR PATHOLOGY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR INVASION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRION; VIRUS CLASSIFICATION; VIRUS LOAD; BLOOD; CLASSIFICATION; PAPILLOMAVIRIDAE; PHYSIOLOGY; SIGNAL TRANSDUCTION; UTERINE CERVIX TUMOR;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 84958818791     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000241     Document Type: Article

References (23)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675-2686.
2. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. (2012). Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 (Suppl 5):F88-F99.
3. ASCUS-LSIL Triage (ALTS) Group (2003). Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 188:1383-1392.
4. Benoy IH, Vanden Broeck D, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, et al. (2011). Prior knowledge of HPV status improves detection of CIN2 + by cytology screening. Am J Obstet Gynecol 205:569.e1-569.e7.
5. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244-265.
6. Constandinou-Williams C, Collins SI, Roberts S, Young LS, Woodman CB, Murray PG (2010). Is human papillomavirus viral load a clinically useful predictive marker?. A longitudinal study. Cancer Epidemiol Biomarkers Prev 19:832-837.
7. Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ, Bogers JJ (2007). Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 11:881-891.
8. Depuydt CE, Arbyn M, Benoy IH, Vandepitte J, Vereecken AJ, Bogers JJ (2009). Quality control for normal liquid-based cytology: rescreening, high-risk HPV targeted reviewing and/or high-risk HPV detection?. J Cell Mol Med 13 (9B):4051-4060.
9. Depuydt CE, Benoy IH, Beert JF, Criel AM, Bogers JJ, Arbyn M (2012). Clinical validation of a type-specific real-Time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening. J Clin Microbiol 50:4073-4077.
10. Depuydt CE, Criel AM, Benoy IH, Arbyn M, Vereecken AJ, Bogers JJ (2012). Changes in type-specific human papillomavirus load predict progression to cervical cancer. J Cell Mol Med 16:3096-3104.
11. Depuydt CE, Jonckheere J, Berth M, Salembier GM, Vereecken AJ, Bogers JJ (2015). Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections. Cancer Med 4:1294-1302.
12. Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, Da Silva D, et al. (2008). European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 19:342-354.
13. Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf JJ, Da Silva D, et al. (2009). European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology 20:5-16.
14. Micalessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE (2011). Highthroughput detection, genotyping and quantification of the human papillomavirus using real-Time PCR. Clin Chem Lab Med 50:655-661.
15. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL (2006). Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-Associated lesions. J Clin Virol 35:270-277.
16. Quint W, Jenkins D, Molijn A, Struijk L, van de Sandt M, Doorbar J, et al. (2012). One virus, one lesion-individual components of CIN lesions contain a specific HPV type. J Pathol 227:62-71.
17. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. (2008). Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100:513-517.
18. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, et al., on behalf of the VALGENT study group (2013). Multiple HPV infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol 51:1458-1464.
19. Schoonjans F, Zalata A, Depuydt CE, Comhaire FH (1995). MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed 48:257-262.
20. Sundström K, Ploner A, Dahlström LA, Palmgren J, Dillner J, Adami HO, et al. (2013). Prospective study of HPV16 viral load and risk of in situ and invasive squamous cervical cancer. Cancer Epidemiol Biomarkers Prev 22:150-158.
21. Wang SM, Colombara D, Shi JF, Zhao FH, Li J, Chen F, et al. (2013). Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses. Int J Gynecol Cancer 23:716-723.
22. Ylitalo N, Josefsson A, Melbye M, Sörensen P, Frisch M, Andersen PK, et al. (2000). A prospective study showing long-Term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 60:6027-6032.
23. Ylitalo N, Sørensen P, Josefsson AM, Magnusson PK, Andersen PK, Pontén J, et al. (2000). Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355:2194-2198.